North America Multiple Hereditary Exostosis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

North America Multiple Hereditary Exostosis Market Segmentation, By Type (Sessile and Pedunculated), Treatment (Surgery, Medication, and Others), Diagnosis (X-ray, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Genetic Tests, and Others), Site (Legs, Arms, Shoulders, Pelvis, Fingers, and Toes), Age Group (Pediatric and Adult), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others) - Industry Trends and Forecast to 2032

North America Multiple Hereditary Exostosis Market Size

• The North America multiple hereditary exostosis market size was valued at USD 51.36 million in 2024 and is expected to reach USD 65.57 million by 2032, at a CAGR of 3.10% during the forecast period
• The market growth is largely driven by increased awareness, earlier diagnostic capabilities, and expanding genetic testing services, which have improved identification and clinical management of MHE across the region
• Furthermore, growing investments in orphan disease research, patient support initiatives, and novel treatment options such as gene therapies and targeted drug development are positioning MHE care as a vital part of rare disease healthcare frameworks. These synergistic developments are enhancing treatment pipelines and patient access, thereby significantly accelerating market growth

North America Multiple Hereditary Exostosis Market Analysis

• Multiple Hereditary Exostosis (MHE), a rare genetic disorder characterized by the development of multiple benign bone tumors, is gaining increasing attention in North America due to advances in diagnostic technologies, growing disease awareness, and the expansion of specialized treatment centers
• The rising demand for early diagnosis and tailored therapeutic approaches is primarily fueled by enhanced access to genetic testing, supportive healthcare policies, and increased focus on rare disease management by public and private sectors
• U.S. dominated the North America multiple hereditary exostosis market with the largest revenue share of 45.8% in 2024, driven by a strong healthcare infrastructure, active rare disease research programs, and the presence of leading biopharmaceutical companies engaged in orphan drug development and clinical trials
• Canada is expected to be the fastest growing country in the North America multiple hereditary exostosis market during the forecast period due to rising awareness initiatives, expanded rare disease registries, and growing access to specialized healthcare services
• The genetic tests segment dominated the North America multiple hereditary exostosis market with a market share of 49.2% in 2024, attributed to its essential role in early detection, family screening, and enabling individualized treatment plans

Report Scope and North America Multiple Hereditary Exostosis Market Segmentation        

North America Multiple Hereditary Exostosis Market Trends

“Increased Emphasis on Early Diagnosis and Precision Care”

• A significant and accelerating trend in the North America MHE market is the growing focus on early diagnosis and precision treatment through the use of advanced genetic screening, imaging, and individualized care strategies. These developments are enabling better disease identification and proactive clinical management for patients at various stages

  • For instance, institutions such as Boston Children’s Hospital and the Mayo Clinic are leveraging next-generation sequencing technologies to identify EXT1 and EXT2 mutations in at-risk individuals, enabling early-stage detection and surveillance. In parallel, pediatric orthopedic clinics are adopting advanced imaging tools for more accurate monitoring of exostosis progression

• The integration of genetic insights into clinical decision-making supports tailored treatment plans, including the timing of surgical interventions and risk-based monitoring protocols. Digital health solutions, including patient registries and AI-powered data platforms, are also helping track long-term outcomes and refine clinical guidelines. Furthermore, early diagnosis initiatives are supported by advocacy organizations such as the MHE Research Foundation, which collaborates with researchers and clinicians to improve disease education and care
• The seamless combination of diagnostics, digital platforms, and personalized care planning is enabling healthcare providers to offer proactive treatment pathways, especially in pediatric cases where early intervention can prevent skeletal deformities and mobility issues
• This trend towards more targeted, data-driven, and patient-centric approaches is fundamentally reshaping expectations for MHE care and enhancing quality of life for affected individuals. Consequently, leading U.S. research institutions and biotech firms are exploring the potential of novel gene therapies and disease-modifying interventions
• The demand for precision-based MHE diagnosis and treatment models is growing rapidly across both academic medical centers and specialized pediatric clinics, as families and clinicians increasingly prioritize early detection, minimally invasive care, and long-term disease monitoring

North America Multiple Hereditary Exostosis Market Dynamics

Driver

“Rising Awareness and Expanding Access to Genetic Testing”

• The increasing public and clinical awareness of MHE, along with broader access to genetic testing and specialized diagnostic services, is a major driver accelerating the growth of the MHE market in North America

  • For instance, initiatives by rare disease organizations such as the National Organization for Rare Disorders (NORD) and patient advocacy groups are promoting earlier diagnosis and facilitating more informed clinical decision-making. This is helping families seek genetic counseling and initiate early treatment interventions

• As genetic testing becomes more affordable and widely available, healthcare providers are better equipped to screen high-risk individuals and offer predictive insights. The expanding presence of pediatric orthopedic specialists and academic rare disease centers is further supporting comprehensive care strategies
• Furthermore, the integration of MHE care into multidisciplinary treatment models and institutional rare disease programs is encouraging collaborative research and innovation. The availability of family-based screening, detailed imaging protocols, and dedicated MHE clinics is fostering timely and effective care
• The convenience and accessibility of modern genetic platforms, along with growing acceptance among physicians and caregivers, are propelling adoption in both urban and underserved areas. This progress is contributing to earlier detection and improved clinical outcomes across the North American MHE landscape

Restraint/Challenge

“Limited Disease-Specific Therapies and Underdiagnosis”

• Despite increasing awareness, the MHE market in North America continues to face challenges such as the lack of disease-modifying therapies and frequent underdiagnosis due to the variable nature of symptom presentation, especially in early stages or in mild phenotypes

  • For instance, many individuals with MHE may remain undiagnosed until skeletal deformities or complications emerge, resulting in delayed care. In addition, limited clinical exposure to rare diseases among general practitioners can hinder early detection and referral to specialists

• The absence of FDA-approved treatments that directly target the genetic basis of MHE constrains therapeutic development and results in a reliance on symptomatic and surgical management. While orthopedic surgeries can address deformities and relieve pain, they do not halt disease progression
• Moreover, reimbursement challenges, unequal access to genetic counseling, and disparities in healthcare infrastructure may restrict timely diagnosis and specialized care, particularly in rural or lower-income regions. These limitations can contribute to inconsistent treatment quality and long-term patient burden
• While public-private partnerships and patient advocacy groups are working to improve awareness and access, further efforts in standardizing care pathways, supporting clinical trials, and investing in gene-based therapies will be critical to overcoming existing challenges and ensuring sustainable market growth

North America Multiple Hereditary Exostosis Market Scope

The market is segmented on the basis of type, treatment, diagnosis, site, age group, and end user.

• By Type

On the basis of type, the North America multiple hereditary exostosis market is segmented into sessile and pedunculated. The sessile segment dominated the market with the largest market revenue share in 2024, driven by its higher clinical visibility and association with more severe skeletal complications. Sessile osteochondromas are typically broad-based and often found on major bones, which increases the such aslihood of early detection and surgical intervention. The segment also sees strong demand due to its correlation with mobility issues and deformities that require long-term orthopedic care.

The pedunculated segment is anticipated to witness the fastest growth rate from 2025 to 2032, fueled by increasing diagnostic sensitivity and improved imaging capabilities. Pedunculated lesions, often less symptomatic initially, are being detected more frequently through proactive screening and genetic testing, especially in pediatric patients with a family history of MHE.

• By Treatment

On the basis of treatment, the North America multiple hereditary exostosis market is segmented into surgery, medication, and others. The surgery segment held the largest market revenue share in 2024 driven by its established role as the primary treatment modality for symptomatic lesions, deformities, and nerve compression. Surgical intervention is often necessary to restore mobility, relieve pain, and correct limb length discrepancies, particularly in growing children.

The medication segment is expected to witness the fastest CAGR from 2025 to 2032, driven by the growing use of pain management drugs, anti-inflammatories, and research into targeted molecular therapies. Although currently supportive in nature, medications are becoming an increasingly important component of non-surgical MHE care, especially for patients with mild symptoms or those ineligible for surgery.

• By Diagnosis

On the basis of diagnosis, the North America multiple hereditary exostosis market is segmented into X-ray, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Genetic Tests, and Others. The genetic tests segment dominated the MHE market with a market share of 49.2% in 2024, attributed to its essential role in early detection, family screening, and enabling individualized treatment plans. As genetic counseling becomes a regular part of MHE management, next-generation sequencing and EXT1/EXT2 mutation tests are gaining popularity for at-risk individuals and newly diagnosed pediatric cases.

The X-ray segment is expected to witness fastest growth from 2025 to 2032, driven by its continued use as a first-line, cost-effective diagnostic method in orthopedic and pediatric clinics. Despite being less advanced, X-rays remain widely accessible and serve as a standard initial screening tool for identifying bony outgrowths in symptomatic individuals.

• By Site

On the basis of site, the North America multiple hereditary exostosis market is segmented into legs, arms, shoulders, pelvis, fingers, and toes. The legs segment dominated the market with the largest market revenue share in 2024, driven by the high frequency of exostoses on the femur and tibia, which often result in gait disturbances and limb length discrepancies that require intervention.

The pelvis segment is anticipated to witness the fastest growth rate from 2025 to 2032, fueled by growing awareness of exostoses in deeper skeletal areas. Pelvic lesions, though less visible externally, are increasingly diagnosed due to advancements in imaging technologies such as MRI and CT scans, and they often require complex surgical approaches due to proximity to nerves and internal structures.

• By Age Group

On the basis of age group, the North America multiple hereditary exostosis market is segmented into pediatric and adult. The pediatric segment dominated the market with the largest market revenue share in 2024, driven by the early onset nature of MHE, which typically manifests in childhood. Pediatric patients require consistent monitoring and early interventions to prevent long-term skeletal deformities, making this segment the largest consumer of orthopedic and diagnostic services.

The adult segment is anticipated to witness fastest growth from 2025 to 2032, supported by long-term care requirements, follow-up surgeries, and increased diagnosis of mild or delayed-onset cases. Adults with MHE may also require revision procedures and ongoing management of complications that arise over time.

• By End User

On the basis of end user, the North America multiple hereditary exostosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market revenue share in 2024 driven by the comprehensive services provided in these settings, including diagnosis, imaging, orthopedic surgery, and genetic counseling. Hospitals are often the first point of care for pediatric referrals and complex cases requiring multidisciplinary treatment.

The specialty clinics segment is expected to witness the fastest growth rate from 2025 to 2032, fueled by the emergence of dedicated rare disease and orthopedic clinics offering personalized care. These clinics provide coordinated treatment pathways for MHE patients, including access to genetic counseling, minimally invasive surgery, and long-term follow-up, making them increasingly preferred by families and caregivers seeking specialized expertise.

North America Multiple Hereditary Exostosis Market Regional Analysis

• U.S dominated the North America MHE market with the largest revenue share of 45.8% in 2024, driven by a strong healthcare infrastructure, active rare disease research programs, and the presence of leading biopharmaceutical companies engaged in orphan drug development and clinical trials
• Patients and healthcare providers in the U.S. prioritize early diagnosis and personalized treatment, supported by access to cutting-edge genetic testing, orthopedic expertise, and dedicated rare disease programs across leading pediatric institutions
• This strong market presence is further supported by active patient advocacy organizations, federal funding for rare disease research, and the integration of precision medicine approaches, making the U.S. a central hub for innovation and specialized MHE care in North America

U.S. Multiple Hereditary Exostosis Market Insight

The U.S. multiple hereditary exostosis market captured the largest revenue share of 87% in 2024 within North America, fueled by early genetic screening adoption, advanced pediatric orthopedic infrastructure, and growing public awareness of rare diseases. Leading hospitals and research institutions, such as Boston Children’s Hospital and Mayo Clinic, are pioneering personalized treatment approaches and multidisciplinary care models. Strong support from advocacy groups, coupled with ongoing clinical research into gene-targeted therapies and surgical advancements, is accelerating market expansion. Furthermore, the presence of established rare disease registries and federal initiatives is significantly contributing to the development of a comprehensive care ecosystem for MHE.

Canada Multiple Hereditary Exostosis Market Insight

The Canada multiple hereditary exostosis market is projected to expand at a stable CAGR throughout the forecast period, driven by increasing access to genetic counseling and the expansion of rare disease programs. National health initiatives are promoting awareness and early diagnosis of hereditary skeletal conditions. Pediatric hospitals across major cities, including Toronto and Vancouver, are increasingly adopting integrated care models, enhancing diagnosis and long-term management. In addition, the emphasis on universal healthcare and equity in rare disease treatment access is supporting the gradual uptake of specialized MHE services across provinces.

Mexico Multiple Hereditary Exostosis Market Insight

The Mexico multiple hereditary exostosis market is anticipated to grow at a moderate CAGR during the forecast period, supported by the gradual modernization of the country’s healthcare infrastructure and rising awareness of pediatric bone disorders. Though access to advanced diagnostics remains limited in rural areas, urban healthcare centers are increasingly incorporating imaging and genetic services. Collaborations with international research bodies and advocacy organizations are helping drive education and diagnosis initiatives. As government-backed efforts expand rare disease support and diagnostic capabilities, Mexico is positioned to see increased identification and treatment of MHE cases.

North America Multiple Hereditary Exostosis Market Share

The North America multiple hereditary exostosis industry is primarily led by well-established companies, including:

• Illumina, Inc. (U.S.)
• Medtronic (Ireland)
• Zimmer Biomet (U.S.)
• Stryker (U.S.)
• Siemens Healthineers AG (Germany)
• GE HealthCare (U.S.)
• Canon Medical Systems Corporation (Japan)
• Esaote S.p.A. (Italy)
• Thermo Fisher Scientific Inc. (U.S.)
• F. Hoffmann-La Roche AG (Switzerland)
• Koninklijke Philips N.V. (Netherlands)
• B. Braun SE (Germany)
• Agilent Technologies, Inc. (U.S.)
• PerkinElmer (U.S.)
• FUJIFILM Corporation (Japan)
• Beijing Genomics Institute (BGI Genomics) (China)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• Jiangsu Trautec Medical Technology Co., Ltd. (China)
• Toshiba Corporation (Japan)
• Takara Bio Inc. (Japan)

What are the Recent Developments in North America Multiple Hereditary Exostosis Market?

• In May 2024, the U.S.-based nonprofit MHE Research Foundation launched a new national awareness and education campaign across pediatric hospitals, aimed at promoting early diagnosis of Multiple Hereditary Exostosis through genetic screening and orthopedic evaluation. This initiative highlights the growing emphasis on early intervention and coordinated care in rare skeletal disorders and aims to improve long-term outcomes by supporting timely and accurate diagnosis for at-risk children
• In April 2024, Children’s Hospital of Philadelphia (CHOP) announced the expansion of its Orthopedic Genetics Program, which includes enhanced diagnostic pathways and personalized treatment planning for MHE patients. The program integrates genetic testing with surgical consultation and long-term orthopedic monitoring, positioning CHOP as a leader in multidisciplinary care for hereditary skeletal conditions
• In March 2024, Mayo Clinic initiated a clinical research study focused on understanding long-term complications and surgical outcomes in adults previously diagnosed with MHE in childhood. The study aims to generate evidence-based guidelines for lifelong orthopedic monitoring and inform future therapeutic advancements for skeletal tumor prevention and management
• In February 2024, Canadian-based SickKids Hospital introduced a rare disease genetic panel that includes EXT1 and EXT2 mutation screening for early MHE detection. This addition to the hospital's pediatric genetic services demonstrates growing investment in precision medicine across Canada and a shift toward earlier, more targeted interventions for hereditary bone disorders
• In January 2024, the National Institutes of Health (NIH) provided funding to support the development of a centralized North American MHE Patient Registry, aimed at improving clinical trial recruitment, tracking disease progression, and fostering cross-border collaboration in research. This initiative reflects the region’s strategic focus on data-driven advancements and collaborative approaches to rare disease treatment and care innovation

SKU-73008